Genetic variants in PPARGC1B and CNTN4 are associated with thromboxane A2 formation and with cardiovascular event free survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). by McCarthy, Nina S et al.
                             Elsevier Editorial System(tm) for 
Atherosclerosis 
                                  Manuscript Draft 
 
 
Manuscript Number: ATH-D-17-00958R1 
 
Title: Genetic Variants in PPARGC1B and CNTN4 are Associated with 
Thromboxane A2 Formation and with Cardiovascular Event Free Survival in 
the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).  
 
Article Type: Research paper 
 
Section/Category: Clinical & Population Research 
 
Keywords: Genome wide association study, thromboxane, thrombosis 
 
Corresponding Author: Dr. Nina S. McCarthy,  
 
Corresponding Author's Institution: University of Western Australia 
 
First Author: Nina S. McCarthy 
 
Order of Authors: Nina S. McCarthy; Ciara Vangjeli; Praveen Surendran; 
Achim  Treumann; Cathy Rooney; Emily Ho; Peter Sever; Simon Thom; Alun 
Hughes; Patricia Munroe; Philip Howard; Toby Johnson; Mark Caulfield; 
Denis Shields; Eoin O'Brien; Desmond Fitzgerald; Alice Stanton 
 
Abstract: Background and aims: Elevated urinary 11-dehydro thromboxane B2 
(TxB2), a measure of thromboxane A2 formation in vivo, predicts future 
atherothrombotic events. To further understand this relationship, the 
genetic determinants of 11-dehydro TxB2 and their associations with 
cardiovascular morbidity were investigated in this study. 
 
Methods and Results: Genome-wide and targeted genetic association studies 
of urinary 11-dehydro TxB2 were conducted in 806 Anglo-Scandinavian 
Cardiac Outcomes Trial (ASCOT) participants. The strongest associations 
were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 (rs10510230, 
rs4684343) - these 5 single nucleotide polymorphisms (SNPs) were 
independently associated with 11-dehydro TxB2 formation. Haplotypes of 
11-dehydro TxB2 increasing alleles for both PPARGC1B and CNTN4 were 
significantly associated with 11-dehydro TxB2, explaining 5.2% and 4.5% 
of the variation in the whole cohort, and 8.8% and 7.9% in participants 
not taking aspirin, respectively. In a second ASCOT population (n=6,199), 
addition of these 5 SNPs significantly improved the covariate-only cox 
proportional hazards model for cardiovascular events (chisq=14.7, 
P=0.01). Two of the risk alleles associated with increased urinary 11-
dehydro TxB2 were individually associated with greater incidences of 
cardiovascular events - rs10515638 (HR =1.31, P=0.01) and rs10510230 
(HR=1.25, P=0.007); effect sizes were larger in those not taking aspirin. 
 
Conclusions: PPARGC1B and CNTN4 genotypes are associated with elevated 
thromboxane A2 formation and with an excess of cardiovascular events. 
Aspirin appears to blunt these associations.  
If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin 
is confirmed by additional studies, PPARGC1B and CNTN4 genotyping could 
potentially assist in clinical decision making regarding the use of 
aspirin in primary prevention. 
  
 
 
 
Highlights 
 This paper describes the first genome wide association study of thromboxane A2 formation. 
 It shows that 5 SNPs in two genes, PPARGC1B and CNTN4, are associated with elevated 
thromboxane A2 formation in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) 
participants and with an excess of cardiovascular events in an independent ASCOT 
population (n=6,199).  
 Results indicate specific protection of aspirin for PPARGC1B and CNTN4. If confirmed, 
PPARGC1B and CNTN4 genotyping could potentially provide guidance in the use of aspirin in 
primary prevention. 
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Abstract  
Background and aims: Elevated urinary 11-dehydro thromboxane B2 (TxB2), a measure of 
thromboxane A2 formation in vivo, predicts future atherothrombotic events. To further understand 
this relationship, the genetic determinants of 11-dehydro TxB2 and their associations with 
cardiovascular morbidity were investigated in this study. 
 
Methods and Results: Genome-wide and targeted genetic association studies of urinary 11-dehydro 
TxB2 were conducted in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants. The 
strongest associations were in PPARGC1B (rs4235745, rs32582, rs10515638) and CNTN4 
(rs10510230, rs4684343) – these 5 single nucleotide polymorphisms (SNPs) were independently 
associated with 11-dehydro TxB2 formation. Haplotypes of 11-dehydro TxB2 increasing alleles for 
both PPARGC1B and CNTN4 were significantly associated with 11-dehydro TxB2, explaining 5.2% and 
4.5% of the variation in the whole cohort, and 8.8% and 7.9% in participants not taking aspirin, 
respectively. In a second ASCOT population (n=6,199), addition of these 5 SNPs significantly 
improved the covariate-only cox proportional hazards model for cardiovascular events (chisq=14.7, 
P=0.01). Two of the risk alleles associated with increased urinary 11-dehydro TxB2 were individually 
associated with greater incidences of cardiovascular events - rs10515638 (HR =1.31, P=0.01) and 
rs10510230 (HR=1.25, P=0.007); effect sizes were larger in those not taking aspirin. 
 
Conclusions: PPARGC1B and CNTN4 genotypes are associated with elevated thromboxane A2 
formation and with an excess of cardiovascular events. Aspirin appears to blunt these associations.  
If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional 
studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making 
regarding the use of aspirin in primary prevention. 
 
Key words: Genome wide association study, thromboxane, thrombosis 
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Introduction 
Thromboxane A2 (TxA2) is a potent platelet agonist formed during platelet activation and contributes 
to the risk of arterial thrombosis [1]. Aspirin exerts its major antithrombotic effect by irreversibly 
acetylating platelet cyclo-oxygenase-1 (COX-1), inhibiting production of TxA2. In high risk patients, 
low-dose aspirin reduces the risk of major cardiovascular events by about 20% [2]. Direct 
measurement of TxA2 is not feasible as it is rapidly metabolised in vivo to its stable metabolite, 
thromboxane B2 (TxB2). Measurement of plasma or urinary levels of 11-dehydro TxB2 by mass 
spectrometry gives an accurate reflection of in vivo TxA2 production [3,4]. Increased urinary 11-
dehydro TxB2 concentration is an independent predictor of atherothrombotic events even in aspirin-
treated patients [5,6]. 
 
Measures of TxA2, including urinary [7] and plasma [8] 11-dehydro TxB2 have been shown to be 
heritable in Caucasian populations off and on aspirin (h2 = 0.5-0.7 and 0.2-0.4 respectively). Genetic 
studies have largely focused on the influence of the functional COX-2 single nucleotide 
polymorphism (SNP) rs20417 (–765G>C) on cardiovascular endpoints; a recent meta-analysis 
(n=49,232) reported the minor allele was associated with reduced risk of cardiovascular events and 
lower urinary 11-dehydro TxB2 [9]. 
 
To more comprehensively assess genetic contribution to TxA2 levels, we conducted genome-wide 
and targeted genetic association studies of urinary 11-dehydro TxB2 in a subset of participants from 
the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). In addition, we investigated whether 
variants associated with elevated 11-dehydro TxB2 levels increased the risk of atherothrombotic 
events in a second subset of ASCOT participants.  
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Methods 
The ASCOT trial was a randomized, multicentre trial comparing the long-term effects of two 
antihypertensive regimens on myocardial infarction [10]. The population characteristics, genotyping, 
and imputation of the subsets of ASCOT participants investigated in this study are described in full in 
supplementary material online. All patients gave written informed consent. Written informed 
consent and approval by local research ethics committees and/or institutional review boards were 
obtained for ASCOT, the ASCOT DNA Repository, and the Hypertension Associated Cardiovascular 
Disease (HACVD) sub-study.  
 
Genotypes Associated with Elevated Thromboxane A2: 
Fasting urinary 11-dehydro TxB2 was measured by mass spectrometry in 1,006 participants of the 
HACVD sub-study [11] of the ASCOT trial, and expressed as pg 11-dehydro TxB2 /mg creatinine to 
normalize for urinary output. Genotyping was performed using the genome-wide Illumina 
HumanCNV370-Duo array (CNV370) and/or the Illumina HumanCVD BeadChip (CVD50k, targeting 
>2,000 genic regions related to cardiovascular disease (CVD)), and quality control exclusions applied 
as described previously [12, 13]. After further excluding all copy number variant (CNV) markers and 
SNPs with minor allele frequency (MAF) <5%, 272,166 genotyped SNPs (2,031,499 including imputed 
SNPs) on the CNV370 chip and 31,570 SNPs on the CVD50K chip were analysed in n=777 and n=544 
individuals with 11-dehydro TxB2 measurements, respectively (Supplementary Figure 1). 
 
For each SNP, a linear regression was performed of genotype (assuming an additive genetic model) 
on urinary 11-dehydro TxB2 level (a continuous trait) in PLINK v1.07 [14]. Unless otherwise stated, 
analyses were adjusted for the covariates: age, sex, smoking habit (current smokers vs. never & ex-
smokers), presence of type 2 diabetes, systolic blood pressure (SBP), body mass index (BMI), high 
density lipoprotein (HDL), low density lipoprotein (LDL), randomized anti-hypertensive regimen, 
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6 
reported aspirin use, study location (UK/Ireland or Scandinavia), and the first ten vectors from 
ancestry principal component analysis to avoid confounding due to population stratification. The 
11-dehydro TxB2 measurement was log transformed to an approximately normal distribution prior to 
analysis and quantile-quantile plots did not indicate any inflation of the test statistics 
(Supplementary methods and Supplementary Figures 2 and 3). 
 
Haplotypes were imputed in PLINK using the standard E-M algorithm. Bonferroni threshold for the 
CNV370 chip was P=1.8E-07 (0.05/272,166 genotyped SNPs) to account for multiple testing with a 
5% false positive rate. As many SNPs on the dense CVD50K chip are correlated, correction for the 
21,180 effective tests on the chip is appropriate [13], resulting in a Bonferroni threshold of P=2.4E-
06 (0.05/21,180). SNPs associated at P<1E-03 were considered suggestive of association on both 
chips. 
 
Effect of PPARGC1B and CNTN4 genotypes on Cardiovascular Event Free Survival:  
All ASCOT participants with DNA (n=9,063) were considered for inclusion in the survival analysis. The 
following exclusions were applied: study participants with prior cardiovascular event at baseline 
(n=1,382), other non- ischemic/haemorrhagic event during the study (n=342), self-declared non-
European ancestry (n=370), missing phenotype data or DNA (n=770) (Supplementary Figure 1). The 5 
SNPs independently associated with 11-dehydro TxB2 were successfully genotyped in 6,199 
participants (n=3,369 from Scandinavian centres and n=2,851 from UK/Ireland centres). The primary 
endpoint was a composite endpoint including all ischaemic cardiovascular events and procedures, 
defined as any of: fatal and non-fatal myocardial infarction (MI), fatal and non-fatal heart failure, 
fatal and non-fatal ischaemic stroke and transient ischaemic attack, angina (stable and unstable), 
peripheral arterial disease, revascularization procedures, and retinal vascular thrombosis. Where 
participants had multiple events, the earliest qualifying event was used. The study was stopped after 
5.5 patient-years of follow-up because of benefits of the amlodipine-based regimen on all-cause 
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7 
mortality and stroke outcomes. Study participants with no qualifying event were censored at the 
earlier of the date of withdrawal from the study or the date of study termination (median, range: 5.7 
[1.1-7.1] years).  
 
Survival analyses were conducted using the R packages ‘survival’ version 3.2.0 and ‘survivalROC’ 
version 1.0.3 [15]. The proportional hazards assumption was met for all variables (Supplementary 
Table 1). Multivariate Cox proportional hazards models were used to collectively analyse all clinical 
covariates which were associated with the endpoint of cardiovascular event free survival, plus all 
genotypes. Chi square comparison of the log likelihoods from the covariates-only and full (covariates 
plus SNPs) model was used to test the alternative hypothesis that the addition of thromboxane-
associated SNPs would significantly improve the risk model for CV events. We hypothesized that 
genotypes associated with increased urinary 11-dehydro TxB2 in the association study would be 
inversely correlated with cardiovascular event-free survival, therefore P values and confidence 
intervals reported for individual SNPs are based on a 1-tailed test.  
 
 
Results 
Genotypes Associated with Elevated Thromboxane A2. 
Baseline characteristics of the cohort are shown in Table 1. Approximately half of the patients 
reported taking aspirin at the time of urinary 11-dehydro TxB2 measurement. As expected, 11-
dehydro TxB2 levels were significantly lower in those on aspirin.  
 
Manhattan plots (Figure 1) show that none of the SNPs was individually associated with 11-dehydro 
TxB2 level beyond Bonferroni threshold. There were no associations between COX-1 (PTGS1) and 
COX-2 (PTGS2) SNPs and 11-dehydro TxB2 in this study, even at the suggestive level (P<1E-03, 
Supplementary Table 2). 
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Analysis of CVD50K chip: a PPARGC1B haplotype is significantly associated with 11-dehydro TxB2 
The strongest association signal from the CVD50K chip was in the PPARGC1B (peroxisome 
proliferator-activated receptor gamma, coactivator 1 beta) gene (Figure 1), where 14 SNPs were 
suggestive of association with 11-dehydro TxB2 (Supplementary Table 3). The most significant SNP at 
this locus was rs4235745 (P=4.3E-06, Table 2). Conditioning on rs4235745 genotype, two SNPs 
(rs32582 and rs10515638) remained associated with 11-dehydro TxB2 and were not correlated with 
each other (r2=0.15, Supplementary Table 4, Supplementary Figure 4). Although rs4235745 and 
rs32582 were not genotyped on the CNV370 chip, other variants in the gene did show some 
evidence of association with 11-dehydro TxB2 (Supplementary Table 5 and Figure 1). 
 
The haplotype of 11-dehydro TxB2-increasing alleles of the three independently associated SNPs 
(TTA, frequency 6%) was significantly associated with an increase of 382pg/mg creatinine 11-
dehydro TxB2, surpassing Bonferroni threshold (P=2.0E-06, Table 2). This haplotype explained 5.2% 
of the variation in 11-dehydro TxB2 in all subjects, 8.8% in subjects not on aspirin, and 1.8% in those 
on aspirin (multiple R2 values calculated in R). The 11-dehydro TxB2-decreasing alleles haplotype 
(GCC, frequency 66%) was associated with a decrease of 146pg/mg creatinine (Supplementary Table 
6). 
 
Analysis of CNV370 chip: a CNTN4 haplotype is significantly associated with 11-dehydro TxB2. 
The strongest association signal from the CNV370 analysis was in the CNTN4 (contactin 4) gene 
(Figure 1), where 13 SNPs were suggestive of association with 11-dehydro TxB2 (Supplementary 
Table 7). The most significant genotyped SNP at this locus was rs10510230 (P=5.1E-07, Table 2) and 
conditioning on this genotype revealed one other SNP, rs4684343, independently associated with 
11-dehydro TxB2 and not correlated with rs10510230 (r
2 =0.09, Supplementary Table 8 and 
Supplementary Figure 5). Only one SNP in the CNTN4 gene was genotyped on the CVD50k chip 
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9 
(rs1171387), and this SNP is not very close to either of the top hit CNTN4 SNPs (rs10510230 or 
rs4684343). Hence there was very little signal at the CNTN4 gene on the CVD50K chip 
(Supplementary Table 5 and Figure 1). 
 
The haplotype of both 11-dehydro TxB2–increasing alleles of rs10510230 and rs4684343 (CG, 
frequency 13%) was significantly associated with increased 11-dehydro TxB2, surpassing Bonferroni 
threshold (P=2E-09, Table 2). This haplotype explained 4.5% of the variation in 11-dehydro TxB2 in all 
subjects, 7.9% for subjects not on aspirin, and 1.5% for those on aspirin. The 11-dehydro TxB2-
decreasing alleles haplotype (AA, frequency 44%) was associated with a decrease of 128pg/mg 
creatinine (Supplementary Table 9). 
 
Interaction with aspirin 
The five independently associated PPARGC1B and CNTN4 SNPs showed evidence for interaction with 
aspirin use in a model including the main SNP and aspirin effects and all covariates, with a greater 
association between genotype and 11-dehydro TxB2 in those not taking aspirin (Figure 1, Table 2, 
Supplementary Tables 10 and 11). The interaction was significant for three of these five SNPs after 
correction for multiple testing (P value threshold <0.01; interaction P-values for PPARGC1B SNPs: 
rs4235745 (P=3.3E-04), rs32582 (P= 3.0E-04), rs10515638 (P=0.02) and for CNTN4 SNPs: rs4684343 
(P=0.02), rs10515638 (P= 6.6E-05); Supplementary Tables 10 and 11.  
 
Function of 11-dehydro TxB2 – associated CNTN4 and PPARGC1B SNPs 
None of the independently associated SNPs nor their proxies were in exonic or predicted functional 
regions using the ensemble variant effect predictor (http://www.ensembl.org/Tools/VEP), nor were 
they associated with expression of any genes in any tissues in the GTEx portal 
(http://www.gtexportal.org/home/), (Supplementary Table 12).  
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10 
Effect of PPARGC1B and CNTN4 genotypes on Cardiovascular Event Free Survival.  
Demographic and clinical characteristics of the survival analyses population are shown in Table 1. 
 
Addition of the 11-dehydro TxB2-associated genotypes improves survival model. 
The three PPARGC1B and two CNTN4 independently associated SNPs which comprised the 
haplotypes significantly associated with 11-dehydro TxB2 were included in the survival analysis. The 
addition of these five SNPs significantly improved the covariates-only Cox proportional hazards 
model of cardiovascular event free survival (chisq comparison of the log likelihoods P=0.01, Table 3).  
 
None of the SNPs were associated with any of the cardiovascular risk factors with the exception of a 
slightly increased risk of type 2 diabetes in rs32582 and rs10510230 carriers (Supplementary Table 
13). Results of the univariate survival analysis (Supplementary Table 14) were consistent with those 
reported in the multivariate analysis. There was a small sample overlap between the genetic 
association study and the survival analysis; when these individuals were excluded from the survival 
sample in a sensitivity analysis, it did not alter the overall results (Supplementary Table 15). 
 
 
Two SNPs independently associated with risk of event 
After Bonferroni correction for the 5 SNPs tested (P value threshold <0.01), rs10515638 (PPARGC1B) 
and rs10510230 (CNTN4) were associated with increased risk of event in multivariate (P=0.01 and 
6.9E-03 respectively) and univariate (P=0.03 and P=8.5E-03 respectively) survival models. The 
magnitudes of effect on survival associated with carriage of each minor allele of rs10515638 
(PPARGC1B, HR=1.31) and rs10510230 (CNTN4, HR=1.25) were similar to or greater than those 
associated with increments of 10 years age, 20 mmHg systolic BP, 1 mmol LDL-cholesterol, a 
diagnosis of diabetes mellitus, or use of amlodipine-based antihypertensive therapy in this cohort 
(Table 3).   
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Stratification by aspirin use 
Kaplan Meier plots of survival analysis stratified by aspirin use for the two significant SNPs show that 
effect sizes were larger in subjects not taking aspirin compared to those on aspirin (Figure 2 and 
Supplementary Table 16) and survival receiver operating characteristic (ROC) curves showed that 
addition of the SNPs improved the area under the curve (AUC) for the all subjects and subjects not 
on aspirin samples, but not for those on aspirin (Supplementary Figure 5). However, when 
Aspirin:SNP interaction terms were added to the multivariate survival analysis, none were significant 
beyond correction for multiple testing (Supplementary Table 17). 
 
Stratification by type of event 
Comparing the separate stroke and coronary event analyses, the PPARGC1 SNP (rs10515638) had a 
larger effect size for coronary events (HR 1.41, P=0.002, 433 events) than for stroke events. By 
contrast, despite much lower power in the stroke analysis, the CNTN4 SNP (rs10510230) had a larger 
effect size for stroke (1.31, P=0.17, 57 events) than for coronary events, especially in those not on 
aspirin (HR 2.71, P=0.003, 26 events), Supplementary Table 18. 
 
The 11-dehydro TxB2-associated haplotypes are associated with cardiovascular event free survival. 
Survival analysis of the PPARGC1B and CNTN4 haplotypes which were associated with the highest 
11-dehydro TxB2 levels (Supplementary Table 19 and Supplementary Figure 6) showed that 
carriership of one copy of the PPARGC1B haplotype (HR= 1.21, P=0.05) and of the CNTN4 haplotype 
(HR=1.33, P=0.005), had similar effect sizes on survival to those of the highest effect size SNPs in the 
haplotypes (rs10515638 (HR=1.31, P=0.01) and rs10510230 (HR=1.25, P=0.007) respectively, Table 
3). 
 
Discussion 
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Association analysis of genome-wide and targeted, CVD-based genotype data revealed that a 3-SNP 
haplotype of PPARGC1B and a 2-SNP haplotype of CNTN4 are significantly associated with urinary 
levels of 11-dehydro TxB2, a surrogate measure for thromboxane A2 in the HACVD cohort. The 5 
constituent PPARGC1B/CNTN4 SNPs were genotyped in a second ASCOT cohort, and addition of 
these genotypes to clinical and demographic covariates significantly improved the Cox proportional 
hazards model of cardiovascular event-free survival, with 11-dehydro TxB2-increasing alleles 
associated with reduced event-free survival. In both the genetic association and the survival 
analyses, stratification by aspirin use showed that most of the genetic associations were more 
prominent in those not on aspirin. This may suggest that the genetic variants are primarily 
associated with COX1-synthesized thromboxane A2.  
 
Unfortunately, suitable data were not available to formally replicate the genetic associations with 
11-dehydro TxB2 in an independent cohort. However, our finding that the 11-dehydro TxB2-
increasing alleles of the same genetic variants increase the risk of cardiovascular events in an 
independent population does support our finding that these variants are associated with increased 
11-dehydro TxB2, (an established cardiovascular risk factor). In addition, Mendel’s observation that 
inheritance of one trait should be independent of the inheritance of other traits asserts that it is 
unlikely the same SNPs would be associated with both 11-dehydro TxB2 and CHD unless the 
phenotypes are causally linked. Therefore our finding that the same SNPs are associated with 
increased 11-dehydro TxB2 and increased risk of cardiovascular event (unconfounded by association 
with other measured cardiovascular risk factors) supports a causal relationship between 11-dehydro 
TxB2 and CHD and strengthens the finding by Eickelboom et al that urinary 11-dehydro TxB2 is an 
independent risk factor for atherothrombotic events. Whether the atherosclerosis causes the 
elevated 11-dehydro TxB2 or vice versa, however, cannot be clearly ascertained from these data. 
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All five 11-dehydro TxB2-associated SNPs and their proxies are intronic. They are not in strong LD 
with neighbouring genes and it appears likely therefore that these tagging SNPs implicate PPARGC1B 
and CNTN4, however substantial further work is required to ascertain the true causal variants 
behind the association signals.  
 
The PPARGC1B gene is a member of the peroxisome proliferator-activated receptor gamma 
coactivator-1 (PGC-1) family, along with its homologue, PPARGC1A, and more distant relative PGC-1–
related coactivator (PRC). PPARGC1B and PPARGC1A appear to have overlapping function and they 
exhibit shared, wide tissue expression, especially in heart, skeletal muscle, brain and brown adipose 
tissue [16]. A variety of metabolic programs are regulated by PGC-1s, including in the heart where 
PGC-1s help maintain energy homeostasis and activate a broad program of angiogenic factors [17]. 
PGC-1s can co-activate a large range of transcription factors, including the nuclear receptor PPAR γ 
(Supplementary Figure 7) which plays an important role in metabolism, is anti-atherosclerotic and 
anti-inflammatory, and regulates the expression of many genes involved in atherosclerosis including 
COX-2 [18, 19]. Regulation of COX-2 expression by PPAR γ signalling may be the mechanism whereby 
polymorphisms in PPARGC1B influence thromboxane A2 levels. However, the larger effect size in 
subjects not on aspirin suggest the effect is more likely mediated by the primary aspirin target, COX-
1, or alternatively through influencing substrate availability or enzymes downstream of COX-1 in the 
thromboxane A2 synthetic pathway. It is not known whether PGC-1/ PPAR γ signalling effects 
expression of COX-1.   
 
Contactin 4 is a member of the immunoglobulin superfamily and is a known neuronal membrane cell 
adhesion molecule. CNTN4 expression has been shown in many tissue types other than neuronal, 
however its role(s) there are not known [20].  
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We conducted a search of the term ‘cardiovascular in the NHGRI-EBI GWAS catalogue-
(https://www.ebi.ac.uk/gwas/search?query=cardiovascular, accessed 25/10/17, Supplementary 
Table 20) in order to put our findings in the context of the vast GWAS data now available. The 
CNTN4 gene has been associated with serum uric acid levels in previous genome-wide association 
and linkage studies, [21, 22], which is itself correlated with a variety of CVD risk factors. There is 
some evidence for cross talk between COX and uric acid pathways - uric acid has been shown to 
stimulate COX-2 synthesis [23], for example. Although PPARGC1B does not feature in the GWAS 
catalogue results, genetic polymorphisms in the PPARGC1B genes have previously been putatively 
associated with type 2 diabetes [24, 25].  
 
A search of the five 11-dehydro TxB2 SNPs reported in this study in GWAS central, 
(http://www.gwascentral.org/ accessed 25/10/17), showed that none of the five SNPs have been 
included in GWAS of MI in this catalogue (Supplementary Table 21). Some of the SNPs have shown 
previous nominal associations (P<0.05) with other cardiovascular phenotypes, including associations 
between rs32583 and ischemic stroke (Supplementary Table 21). It should be noted that the five 11-
dehydro TxB2 -associated SNPs in this study were not present on most of the commonly used GWAS 
chips; rs4235745 for example is only on the IBC (CVD50K) chip (Supplementary Table 5). In addition, 
the thromboxane pathway represents one of many risk factors for a cardiovascular disease; 
therefore, we would not necessarily expect the SNPs reported here to be among the top GWAS hits 
for CVD. 
 
Identification of the genetic determinants of thromboxane A2 levels will help to improve our 
understanding of the physiology of this important prothrombotic agent. They may also prove to be 
useful biomarkers for assessing thromboxane levels without the need for urinary thromboxane 
measurement. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed 
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by additional studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision 
making regarding the use of aspirin in primary prevention. 
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Table 1. Baseline characteristics  
Baseline characteristics of the genetic 
association cohort (n=806). 
All Subjects 
(n=806) 
Not On 
Aspirin 
(n=415) 
On Aspirin 
(n=391) 
P 
11-dehydro TxB2, pg/mg creatinine (median,IQR) 507(305-818) 
716(480-
1072) 
331(224-
552) 
2.00E-16 
Age, years (mean±sd) 64.7±8.1 64.2±8.1 65.2±8.09 0.09 
Male (n,%) 626(78%) 336(81%) 290(74%) 0.02 
Current smoker (n,%) 186(23%) 94(23%) 92(23%) 0.77 
Current diabetes (n,%) 150(19%) 55(13%) 95(24%) 6.00E-05 
SBP, mmHg (mean±sd) 135.2±12.0 133.1±12.5 137.4±12.5 2.00E-07 
BMI, kg/m
2
 (mean±sd) 29.2±4.7 29.1±4.7 29.3±4.8 0.53 
HDL, mmol/L (mean±sd) 1.3±0.3 1.3 ± 0.4 1.3±0.3 0.16 
LDL, mmol/L (mean±sd) 3.0±0.9 3.0 ± 0.9 3.0±0.8 0.17 
Amlodipine treatment group (n,%) 407(50%) 215(52%) 192(49%) 0.44 
Baseline characteristics of the survival cohort 
(n=6,199) 
All subjects                     
(n=6,199)  
Not on 
aspirin 
(n=4,355) 
On aspirin 
(n=1,844) 
P 
Age, years (mean±sd) 61.8±8.4 61.2±8.4 63.0±8.1 2.40E-15 
Male (n,%) 4,996(80.6) 3,470(79.7) 1,526(82.7) 5.70E-03 
Current smoker (n,%) 2,007(32.4) 1,525(35.0) 482(26.1) 1.00E-11 
Diabetes, type 2 (n,%) 1,404(22.6) 894(20.5) 510(27.6) 1.10E-09 
SBP, mmHg (mean±sd) 152.7±14.7 153.3±14.9 151.2±14.2 5.40E-07 
BMI, kg/m
2
 (mean±sd) 28.9±4.6 28.8±4.6 29.2±4.6 9.90E-04 
HDL, mmol/L (mean±sd) 1.28±0.34 1.30±0.34 1.25±0.32 1.60E-06 
LDL, mmol/L (mean±sd) 3.79±0.91 3.78±0.89 3.81±0.95 0.4 
UK/Ireland cohort (n,%) 2,830(45.6) 1,534(35.2) 1,296(70.3) <2.2E-16 
Amlodipine treatment group (n,%) 3,153(50.9) 2,231(51.2) 922(50.0) 0.39 
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17 
Follow-up, years (median, IQR) 5.6(5.1-6.0) 5.7(5.2-6.1) 5.5(5.0-6.0) 6.60E-15 
n events (composite endpoint) 477(7.7) 189(4.3) 288(15.6) <2.2E-16 
n events per 100 person-years (95%CI) 1.40(1.28-1.53) 
0.77(0.67-
0.90) 
2.98(2.64-
3.34) 
<2.2E-16 
   -Coronary revascularisation procedure (n) 149 55 94 <2.2E-16 
   -Non-fatal MI (incl. silent) + fatal CHD (n) 271 108 163 <2.2E-16 
   -Ischemic stroke (n) 44 15 29 9.20E-08 
   -Other (n) 13 11 2 0.46 
Amlodipine treatment group: membership of amlodipine (vs atenolol) regime. SBP: Systolic blood 
pressure; BMI: Body mass index; HDL: High density lipoprotein; LDL: Low-density lipoprotein. 
UK/Ireland: UK/Ireland (vs Scandinavian) centres. Composite endpoint: total ischaemic 
cardiovascular events/procedures as described in methods. MI: myocardial infarction. CHD: coronary 
heart disease. IQR: Inter quartile range; SD: Standard deviation; 95% CIs for events were calculated 
using an exact Poisson test.  P:  comparison of on-aspirin and not-on-aspirin groups (Student's t-test 
or Mann-Whitney U test for normally and non-normally distributed variables respectively, or 
Pearson's chi-squared test of proportions). 
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Table 2. PPARGC1B and CNTN4 SNPs independently associated with 11-dehydro TxB2.   
PPARGC1B            all subjects (n=544) 
subjects not on aspirin 
(n=276) 
subjects on aspirin 
(n=268) 
Chr SNP Position MAF A1/2  r
2
   D' beta P P 
SNP*Asp
 beta P beta P 
5 rs10515638 intron 1 0.08 T/G 0.07 0.58 233.1  7.30E-04 0.02 391.9 1.90E-03 74.7 0.12 
5 rs4235745 intron 1 0.3 T/C NA NA 166.7 4.30E-06 3.30E-04 284.9 2.20E-05 50.5 0.06 
5 rs32582 intron 2 0.18 A/C 0.42 0.93 201.1 9.10E-06 3.00E-04 353.1 2.10E-05 45.4 0.18 
3-SNP minor allele 
haplotype 
0.06 TTA     382.4 2.10E-06   658.7 9.50E-06 105.5 8.00E-02 
CNTN4           all subjects (n=772) 
subjects not on aspirin 
(n=396) 
subjects on aspirin 
(n=376) 
Chr SNP Position MAF A1/2  r
2
   D' beta P P 
SNP*Asp
 beta P beta P 
3 rs10510230 intron 1 0.15 C/A NA NA 189.8 5.10E-07 6.60E-05 329.5 1.50E-07 37.6 0.34 
3 rs4684343 intron 2 0.45 A/G 0.1 0.77 -133.4 8.80E-07 1.90E-02 -194.6 2.50E-05 -65.2 0.02 
2-SNP minor/major allele 
haplotype  
0.13 CG     249 2.00E-09   456.2 1.30E-10 48.4 0.24 
CHR: chromosome, BP: base pair position, MAF: minor allele frequency, beta: change in 11-dehydro TxB2 associated with one copy of the minor allele / 
haplotype. Position: of the SNP in the PPARGC1B gene, r2:  squared correlation coefficient between the genotype of the SNP and the top hit SNP in the gene 
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(rs4235745 for PPARGC1B and rs10510230 for CNTN4). D’: the normalised coefficient of linkage disequilibrium between the genotype of the SNP and the 
top hit SNP in the gene. A1: major allele, A2: minor allele. 
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Table 3. Multivariate Cox proportional hazards analysis all significant clinical covariates plus the 
five 11-dehydro TxB2-associated SNPs with a composite cardiovascular endpoint of all ischaemic 
cardiovascular events and procedures. 
All subjects (n=6,199, 477 ischaemic cardiovascular events) 
  HR  95% CI P  
Age (yrs) 1.02 1.01-1.04 7.70E-05 
Male sex 1.54 1.17-2.02 2.00E-03 
Current smoker 1.43 1.17-1.74 0.03 
Type 2 diabetes 1.12 0.92-1.37 5.30E-04 
SBP (mmHg) 1.01 1.00-1.02 0.06 
BMI (kg/m2) 0.98 0.95-1.00 0.25 
HDL (mmol/L) 0.44 0.31-0.62 8.90E-05 
LDL (mmol/L) 1.21 1.10-1.34 1.80E-06 
Amlodipine treatment 0.82 0.68-0.98 1.40E-04 
Aspirin use 4.68 3.84-5.71 < 2e-16 
UK/Ireland cohort 0.56 0.45-0.68 2.10E-08 
rs4235745 (per minor (T) allele) 0.84 0.71-0.99 0.96 
rs32582 (per minor (A) allele) 1.00 0.82-1.21 0.48 
rs10515638 (per minor (T) allele) 1.31 1.08-1.58 0.01 
rs10510230 (per minor (C) allele) 1.25 1.08-1.46 6.90E-03 
rs4684343 (per minor (G) allele) 1.04 0.93-1.17 0.28 
LRT comparison with covariates-only model:  chisq 14.7 on 5 df, p= 0.01 
The primary endpoint was a composite endpoint including all ischaemic cardiovascular events and 
procedures, defined as any of: fatal and non-fatal MI, fatal and non-fatal heart failure, fatal and non-
fatal ischaemic stroke and transient ischaemic attack, angina (stable and unstable), peripheral 
arterial disease, revascularization procedures, and retinal vascular thrombosis. The Cox proportional 
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hazards model included all SNP genotypes and all covariates. Df: degrees of freedom. SNP statistics 
are based a one-tailed test; where the observed direction of effect is opposite to that predicted, 1-P 
is reported and 95% CI excludes the lower 5% of the distribution. For all SNPs, minor alleles were 
associated with increased 11-dehydro TxB2. SBP: systolic blood pressure. BMI: body mass index. HDL: 
high density lipoprotein cholesterol. LDL: low density lipoprotein cholesterol. Amlodipine treatment 
group: membership of amlodipine (vs atenolol) regime. UK/Ireland: UK/Ireland: UK/Ireland (vs 
Scandinavian) centres participants at UK/Ireland centres vs Scandinavian participants. LRT: likelihood 
ratio test, comprising the chisq (chi squared) comparison of the log likelihoods of the covariates-only 
and covariates-plus-genotypes models. 
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Figures 
 
Figure 1. Association with 11-dehydro TxB2 for the 31,570 SNPs (MAF≥0.05) on the CVD50K chip (A) 
and 2,031,499 SNPs (MAF≥0.05) on the CNV370 chip (B). X-axis: chromosomal location. All SNP 
associations were adjusted for age, sex, smoking habit, diabetes, systolic blood pressure, BMI, HDL, 
LDL, aspirin and anti-hypertensive regimen. The lower dashed lines are the threshold for ‘suggestive’ 
association (P<1E-03), and the upper dashed lines are the Bonferroni threshold for significance 
(P<2.4E-06 for the CNV50K chip and P=1.8E-07 for the CNV370K chip). The most strongly associated 
locus in all subjects on the CVD50K chip, PPARGC1B, is coloured in red and on the CNV370 chip, 
CNTN4, is coloured in blue. 
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Figure 2. Kaplan Meier plot of survival by genotype for the two SNPs independently associated 
with cardiovascular event-free survival, rs10515638 (PPARGC1B) and rs10510230 (CNTN4). 
‘Carriers’: carriers of one or more minor allele. ‘Non carriers’: major allele homozygotes. HR: Hazard 
ratio for the SNP in the multivariate Cox proportional hazards analysis , and corresponding P value 
(Table 3).  
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Dear Editor, 
 
Thank you for considering our manuscript for publication in Atherosclerosis. We appreciate the 
reviewers’ time, positive remarks and helpful suggestions. We have responded to individual 
comments below. 
 
We have used text formatting for clarity as follows: 
Blue upright font = our responses 
Black upright font = reviewers’ comments 
Black italic font = unchanged manuscript text 
Red italic font = revised manuscript text 
 
 
Reviewer #1:  
Comment 1: This is an interesting pharmacogenomic exploration. However, replication in an 
independent population must be performed to enable interpretation of the results. A larger 
population will give opportunities for a more convincing Mendelian randomization approach for 11-
dehydro TxB2 and also allow more formal multiple way analyses of variance in treatment subgroups.  
We agree that an independent replication in a large cohort is desirable. Unfortunately, 11-dehydro 
TxB2 is not an easily measured phenotype, and we have not been able to identify a suitable 
replication population. Although not a formal replication of the association between the genetic 
variants and 11-dehydro TxB2, the finding that the same variants increase the risk of cardiovascular 
events in an independent population does back up our finding that these genetic variants increase 
11-dehydro TxB2 levels.  
 
We have amended the following paragraph in the discussion section:  
‘Unfortunately, suitable data were not available to formally replicate the genetic associations with 
11-dehydro TxB2 in an independent cohort. However, our finding that the 11-dehydro TxB2-increasing 
alleles of the same genetic variants increase the risk of cardiovascular events in an independent 
population does support our finding that these variants are associated with increased 11-dehydro 
TxB2, (an established cardiovascular risk factor). In addition, Mendel’s observation that inheritance of 
one trait should be independent of the inheritance of other traits asserts that it is unlikely the same 
*Point-by-Point Response
SNPs would be associated with both 11-dehydro TxB2 and CHD unless the phenotypes are causally 
linked. Therefore our finding that the same SNPs are associated with increased 11-dehydro TxB2 and 
increased risk of cardiovascular event (unconfounded by association with other measured 
cardiovascular risk factors) supports a causal relationship between 11-dehydro TxB2 and CHD and 
strengthens the finding by Eickelboom et al that urinary 11-dehydro TxB2 is an independent risk 
factor for atherothrombotic events. Whether the atherosclerosis causes the elevated 11-dehydro 
TxB2 or vice versa, however, cannot be clearly ascertained from these data.’ 
 
Comment 2: Moreover, the findings about the relationship with cardiovascular events must be 
discussed in context of the previous large GWA studies. 
We have added the following text to the discussion section, plus supplementary tables 5, 20 and 21, 
which we hope addresses this valid comment.  
‘We conducted a search of the term ‘cardiovascular in the NHGRI-EBI GWAS catalogue-
(https://www.ebi.ac.uk/gwas/search?query=cardiovascular, accessed 25/10/17, Supplementary 
Table 20) in order to put our findings in the context of the vast GWAS data now available. The CNTN4 
gene has been associated with serum uric acid levels in previous genome-wide association and 
linkage studies, [21, 22], which is itself correlated with a variety of CVD risk factors. There is some 
evidence for cross talk between COX and uric acid pathways - uric acid has been shown to stimulate 
COX-2 synthesis [23], for example. Although PPARGC1B does not feature in the GWAS catalogue 
results, genetic polymorphisms in the PPARGC1B genes have previously been putatively associated 
with type 2 diabetes [24, 25].  
 
A search of the five 11-dehydro TxB2 SNPs reported in this study in GWAS central, 
(http://www.gwascentral.org/ accessed 25/10/17), showed that none of the five SNPs have been 
included in GWAS of MI in this catalogue (Supplementary Table 21). Some of the SNPs have shown 
previous nominal associations (P<0.05) with other cardiovascular phenotypes, including associations 
between rs32583 and ischemic stroke (Supplementary Table 21). It should be noted that the five 11-
dehydro TxB2 -associated SNPs in this study were not present on most of the commonly used GWAS 
chips; rs4235745 for example is only on the IBC (CVD50K) chip (Supplementary Table 5). In addition, 
the thromboxane pathway represents one of many risk factors for a cardiovascular disease; 
therefore, we would not necessarily expect the SNPs reported here to be among the top GWAS hits 
for CVD.’ 
 
 
Reviewer #2:  
I find the post-GWAS study and the related manuscript by McCarthy and colleagues potentially 
interesting. Although the design of the study is a bit unusual, it is clear. Also the manuscript is nicely 
written. 
Thank you for your positive comments. 
 
Comments: 
 
Comment 1: The concept of selecting best hits from two separate ChIPs is intriguing. However, the 
question arises, why the overlap between the results from those two SNPs is limited? Or there are 
some additional hits showing the overlap between the chips? Theoretically, at least some top-
scoring results should overlap, even considering methodological differences (selection of the SNPs) 
between the SNPs. 
 
The two chips were quite different in term of their SNPs content, as noted in supplementary 
information section “quality control and imputation”:  
‘merging of the two datasets would have incurred substantial loss of information - 5,328 SNPs were 
unique to the CVD50K chip following quality control – and they were therefore analyzed separately’.  
 
We have highlighted SNPs in both the CNTN4 and PPARGC1B genes on both chips in the amended 
Manhattan plots (Figure 1). We have also added Supplementary Table 3 which shows the results of 
CNTN4 and PPARGC1B SNPs on both chips, and amended the results section as follows: 
‘Analysis of CNV370 chip: a CNTN4 haplotype is significantly associated with 11-dehydro TxB2. 
The strongest association signal from the CNV370 analysis was in the CNTN4 (contactin 4) gene 
(Figure 1), where 13 SNPs were suggestive of association with 11-dehydro TxB2 (Supplementary Table 
7). The most significant genotyped SNP at this locus was rs10510230 (P=5.1E-07, Table 2) and 
conditioning on this genotype revealed one other SNP, rs4684343, independently associated with 11-
dehydro TxB2 and not correlated with rs10510230 (r
2 =0.09, Supplementary Table 8 and 
Supplementary Figure 5). Only one SNP in the CNTN4 gene was genotyped on the CVD50k chip 
(rs1171387), and this SNP is not very close to either of the top hit CNTN4 SNPs (rs10510230 or 
rs4684343). Hence there was very little signal at the CNTN4 gene on the CVD50K chip 
(Supplementary Table 5 and Figure 1).’ 
 
Comment 2: If no SNP reached genome-wide significance after correction for multiple testing, why 
only one region per each chip was selected for further analysis of haplotypes? Looking at the 
Manhattan plots, there are some other hits with or without stratification for aspirin (especially in 
subjects on aspirin). 
Our a priori analysis plan was to take only the top association peaks from each chip forward for 
survival analysis to avoid a high burden of multiple testing. In addition, although the individual SNPs 
were not genome-wide significant, both the PPARGC1B and the CNTN4 haplotypes using the 5 
independently associated SNPs were, so we took forward the SNPs which comprised these genome-
wide significant haplotypes. We will include the 11-dehydro TxB2 association results in their entirety 
as supplementary information so that future studies will hopefully explore the other interesting 
associations. 
 
 
Comment 3: The Authors consider their survival analysis as a replication of the discovery 
associations (page 10, lines 52-57). I would not go that far. If those results are reported as an 
extension/expansion of the discovery results, it is enough. 
We agree with this comment, and hence we have changed the wording of the relevant paragraph in 
the discussion section to read: 
‘Unfortunately, suitable data were not available to formally replicate the genetic associations with 
11-dehydro TxB2 in an independent cohort. However, our finding that the 11-dehydro TxB2-increasing 
alleles of the same genetic variants increase the risk of cardiovascular events in an independent 
population does support our finding that these variants are associated with increased 11-dehydro 
TxB2, (an established cardiovascular risk factor). In addition, Mendel’s observation that inheritance of 
one trait should be independent of the inheritance of other traits asserts that it is unlikely the same 
SNPs would be associated with both 11-dehydro TxB2 and CHD unless the phenotypes are causally 
linked. Therefore our finding that the same SNPs are associated with increased 11-dehydro TxB2 and 
increased risk of cardiovascular event (unconfounded by association with other measured 
cardiovascular risk factors) supports a causal relationship between 11-dehydro TxB2 and CHD and 
strengthens the finding by Eickelboom et al that urinary 11-dehydro TxB2 is an independent risk 
factor for atherothrombotic events. Whether the atherosclerosis causes the elevated 11-dehydro 
TxB2 or vice versa, however, cannot be clearly ascertained from these data.’ 
 
 
Comment 4: By this occasion, if the major findings of the discovery phase were obtained for 
haplotypes, why the survival analysis is conducted for single SNPs (especially if you consider survival 
analysis a replication)? 
Our main finding from the survival analysis was that the addition of all 5 SNPs contributing to the 
two haplotypes together improved the survival model over covariates alone, rather than the 
individual associations, which were just provided for completeness. However, we have added a 
formal analysis of the haplotypes to the supplementary data (Supplementary Table 19 and 
Supplementary Figure 6), and added a section to the manuscript results: 
‘The 11-dehydro TxB2-associated haplotypes are associated with cardiovascular event free survival. 
Survival analysis of the PPARGC1B and CNTN4 haplotypes which were associated with the highest 11-
dehydro TxB2 levels (Supplementary Table 19 and Supplementary Figure 6) showed that carriership of 
one copy of the PPARGC1B haplotype (HR= 1.21, P=0.05) and of the CNTN4 haplotype (HR=1.33, 
P=0.005), had similar effect sizes on survival to those of the highest effect size SNPs in the haplotypes 
(rs10515638 (HR=1.31, P=0.01) and rs10510230 (HR=1.25, P=0.007) respectively, Table 3).’ 
 
 
Comment 5: Page 9, lines 4-10. I would suggest some additional analysis here. Even if the 5 major 
SNPs were not (in silico) functional, their LD-proxies might have been. LD-proxies of those SNPs 
should be determined (using e.g. SNAP software; 
https://www.broadinstitute.org/mpg/snap/ldsearch.php) and check for their experimental 
(literature) and/or in silico function as described elsewhere 
(https://www.ncbi.nlm.nih.gov/pubmed/22909159, 
https://www.ncbi.nlm.nih.gov/pubmed/24866380, 
https://www.ncbi.nlm.nih.gov/pubmed/26473826,  
https://www.ncbi.nlm.nih.gov/pubmed/24930997). 
 
We have added a table (Supplementary Table 12) showing all of the proxy SNPs and their 
annotations (from ensembl and GTEx). None of the LD proxies were exonic, or predicted to have 
high functional consequence. We have changed the relevant paragraph to read:  
‘Function of 11-dehydro TxB2 – associated CNTN4 and PPARGC1B SNPs 
None of the independently associated SNPs nor their proxies were in exonic or predicted functional 
regions using the ensemble variant effect predictor (http://www.ensembl.org/Tools/VEP), nor were 
they associated with expression of any genes in any tissues in the GTEx portal 
(http://www.gtexportal.org/home/), (Supplementary Table 12).’ 
 
 
Comment 6: Figure 2. How can you describe the magnitude of the observed effects? Is it large or 
small?  
The magnitude of the effect of the lead SNPs on cardiovascular free survival (Figure 2) could be 
described as ‘moderate’ – they are similar in magnitude to other CV risk factors (Table 3) and to the 
hazard ratios for the risk haplotypes (see above response). The relevant text in the paper is below: 
‘Two SNPs independently associated with risk of event 
After Bonferroni correction for the 5 SNPs tested (P value threshold <0.01), rs10515638 (PPARGC1B) 
and rs10510230 (CNTN4) were associated with increased risk of event in multivariate (P=0.01 and 
6.9E-03 respectively) and univariate (P=0.03 and P=8.5E-03 respectively) survival models. The 
magnitudes of effect on survival associated with carriage of each minor allele of rs10515638 
(PPARGC1B, HR=1.31) and rs10510230 (CNTN4, HR=1.25) were similar to or greater than those 
associated with increments of 10 years age, 20 mmHg systolic BP, 1 mmol LDL-cholesterol, a 
diagnosis of diabetes mellitus, or use of amlodipine-based antihypertensive therapy in this cohort 
(Table 3).’ 
 
Comment 7: If haplotype analysis is used, it would be good to show in Table 2 also D' between the 
major SNPs. Also the structure of the particular haplotypes with frequencies should be given 
somewhere. 
We agree with this comment and therefore have made the following changes: 
D’ has been added to Table 2.  
The lower panel of Supplementary Table 6 shows all haplotypes of the three SNPs in PPARGC1B 
independently associated with 11-dehydro TxB2 and their frequencies. Similarly, the lower panel of 
Supplementary Table 9 shows all haplotypes of the two CNTN4 SNPs independently associated with 
11-dehydro TxB2.and their frequencies.  
 
 
Other comments: 
1. Page 10, line 2. "Table 5"? Or "Table 3"? -  
We thank the reviewer for identification of this error, and have now corrected the text to “Table 3” 
 
2. Page 9, lines 37-38. "(…) was consistent the multivariate (…)"? Or "(…) was consistent with 
the multivariate (…)"? 
We thank the reviewer for identification of this lack of clarity and have reworded the 2 sentences to 
read:  
‘None of the SNPs were associated with any of the cardiovascular risk factors with the exception of a 
slightly increased risk of type 2 diabetes in rs32582 and rs10510230 carriers (Supplementary Table 
13). Results of the univariate survival analysis (Supplementary Table 14) were consistent with those 
reported in the multivariate analysis. There was a small sample overlap between the genetic 
association study and the survival analysis; when these individuals were excluded from the survival 
sample in a sensitivity analysis, it did not alter the overall results (Supplementary Table 15).’ 
 
3. Page 9, lines 49-55. What do you mean here? What does "range" correspond to (i.e. what is 
between e.g. 21% and 27%)? 
We thank the reviewer for identification of this lack of clarity and have changed the text to read: 
‘The magnitudes of effect on survival associated with carriage of each minor allele of rs10515638 
(PPARGC1B, HR=1.31) and rs10510230 (CNTN4, HR=1.25) were similar to or greater than those 
associated with increments of 10 years age, 20 mmHg systolic BP, 1 mmol LDL-cholesterol, a 
diagnosis of diabetes mellitus, or use of amlodipine-based antihypertensive therapy in this cohort 
(Table 3).   
 
4. The title. I would remove "elevated" and "reduced" as long as alleles are not mentioned. 
We also agree with this point and have therefore changed the title to: 
‘Genetic Variants in PPARGC1B and CNTN4 are Associated with Thromboxane A2 Formation and with 
Cardiovascular Event Free Survival in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).’ 
 
 
5. Page 12, lines 30-36. I would remove this sentence since it is overstatement. I would also 
(especially) remove it from the abstract (it is identical there). 
We do understand this point, and while we certainly do not want to make any unwarranted claim, 
we also believe that it is important to outline the potential clinical implications of this work. Hence 
we have reworded the sentence to try to make it clear that more work will need to be done before 
these findings are clinically useful: 
‘If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is confirmed by additional 
studies, PPARGC1B and CNTN4 genotyping could potentially assist in clinical decision making 
regarding the use of aspirin in primary prevention.’ 
 
 
Reviewer #3: Manuscript Number: ATH-D-17-00958 
 
Genetic Variants in PPARGC1B and CNTN4 are Associated with Elevated Thromboxane A2 Formation 
and with Reduced Cardiovascular Event Free Survival in the Anglo-Scandinavian Cardiac Outcomes 
Trial (ASCOT) 
 
This study sought to identify genetic determinants of urinary 11-dehydro thromboxane B2 (TxB2) 
and their associations with cardiovascular morbidity. Genome-wide association study between 
urinary 11-dehydro TxB2 and SNP genotypes showed suggestive associations with 3 variants in 
PPARGC1B and with 2 variants in CNTN4 using 806 Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT) study subjects. Two of the variants previously identified were also associated with increased 
risk of cardiovascular events in an independent sample from ASCOT (n=6199), and it appears that 
these effects were blunted by aspirin intake. 
 
Although the study is well done, presentation of the results is not always clear. To make this paper 
easier to for a reader to understand, following points should be addressed: 
 
Comment 1: It is not clear why significance level for CNV370 was set to P<1.8E-7 (0.05/272,166) and 
not conventionally used P<5-8. According to Methods section, there were 2,031,499 
genotyped/imputed SNPs after QC. Also, threshold for suggestive association should be indicated for 
separately for CNV370 and CVD50K separately in the methods section.  
We thank the reviewer for identification of this lack of clarity.  
The CNV370K is an older chip with less genotyped SNPs than more modern chips which have much 
higher coverage and for which the more conventional P<5-8 is used (estimated to cover the whole 
genome at Bonferroni correction after LD has been accounted for).  
Only 272,166 SNPs were genotyped on the CNV370 chip, hence Bonferroni being set at 0.05/272,166 
(as the imputed SNPs are based on the information from the genotyped SNPs, no additional 
correction is necessary).  
We have changed the relevant text in the methods section to make these points more clearly: 
‘Genotypes Associated with Elevated Thromboxane A2: 
……. After further excluding all copy number variant (CNV) markers and SNPs with minor allele 
frequency (MAF) <5%, 272,166 genotyped SNPs (2,031,499 including imputed SNPs) on the CNV370 
chip and 31,570 SNPs on the CVD50K chip were analysed in n=777 and n=544 individuals with 11-
dehydro TxB2 measurements, respectively (Supplementary Figure 1)…. 
……………………… Haplotypes were imputed in PLINK using the standard E-M algorithm. Bonferroni 
threshold for the CNV370 chip was P=1.8E-07 (0.05/272,166 genotyped SNPs) to account for multiple 
testing with a 5% false positive rate. As many SNPs on the dense CVD50K chip are correlated, 
correction for the 21,180 effective tests on the chip is appropriate [13], resulting in a Bonferroni 
threshold of P=2.4E-06 (0.05/21,180). SNPs associated at P<1E-03 were considered suggestive of 
association on both chips.’ 
 Comment 2: Significant and suggestive cut offs should be also added to footnotes of each 
table/figure. It would be helpful if suggestive threshold was also added to manhattan plots.  
We thank the reviewer for this suggestion. A suggestive threshold has been added to the Manhattan 
plots (Figure 1), along with the following text:  
‘The lower dashed line is the threshold for ‘suggestive’ association (P<1E-03), and the upper dashed 
line is the Bonferroni threshold for significance (P<2.4E-06 for the CNV50K chip and P=1.8E-07 for the 
CNV370K chip).’ 
 
Moreover, when testing 5 SNPs for interaction, significance level should be P<0.05/5=0.01, instead 
of P<0.05. 
We agree with this comment. This error has been corrected in the revised version, with the 
interactions described in a new paragraph: 
‘Interaction with aspirin 
The five independently associated PPARGC1B and CNTN4 SNPs showed evidence for interaction with 
aspirin use in a model including the main SNP and aspirin effects and all covariates, with a greater 
association between genotype and 11-dehydro TxB2 in those not taking aspirin (Figure 1, Table 2, 
Supplementary Tables 10 and 11). The interaction was significant for three of these five SNPs after 
correction for multiple testing (P value threshold <0.01; interaction P-values for PPARGC1B SNPs: 
rs4235745 (P=3.3E-04), rs32582 (P= 3.0E-04), rs10515638 (P=0.02) and for CNTN4 SNPs: rs4684343 
(P=0.02), rs10515638 (P= 6.6E-05); Supplementary Tables 10 and 11.’ 
 
 
Comment 3: Reported associations should always include p-values throughout the manuscript, 
rather than stating that an association was significant because it was less than a specific cut off. 
We agree with this suggestion, and have amended accordingly throughout in the revised 
manuscript. 
 
 
Comment 4: Cox Proportion Hazards Analysis (Table 3): This table needs major revision.  
 
- First, outcome name should be included the table header (e.g. composite cardiovascular 
evets) and footnotes should have a definition for the outcome (including fatal and non-fatal MI, 
ischemic stroke etc.)  
The title of table 3 has been revised accordingly as follows: 
‘Table 3. Multivariate Cox proportional hazards analysis all significant clinical covariates plus the 
five 11-dehydro TxB2-associated SNPs with a composite cardiovascular endpoint of all ischaemic 
cardiovascular events and procedures.’ 
 
- It is not necessary to show the effect of individual covariates. Instead, a final model should 
be build and individual SNP Hazard Ratios for each SNP should be reported (covariates + SNP1, 
covariates + SNP2 etc.). If so desired, final analysis can include covariates + all 5 SNPs. Example 
below. 
Outcome     
SNP Event rate HR 95% CI p-value (LRT) 
SNP1     
SNP2     
SNP3     
SNP4     
SNP5     
SNP1-5     
As genomic context is important, we decided to make our primary analysis a complete model 
including all SNPs and all covariates. However, univariate analysis of SNPs individually is included in 
Supplementary Table 14. We have removed the covariates-only analysis from Table 3, but reported 
the effects of the covariates in the full model as it is useful to see the magnitude of the hazard ratios 
of the covariates in comparison to those of the SNPs. 
 
 
Comment 5: It would be interesting to see if any of the individual outcomes forming the composite 
outcome is driving the associations. You may not have enough power to see significant associations 
if the composite outcome is broken down, but it may give us additional information Example below. 
 
 SNP1    SNP2     
 Event Rate HR 95% CI p-value (LRT) Event Rate HR 95% CI p-value 
(LRT) ETC. 
Outcome1          
Outcome2          
Outcome3          
Outcome4          
Outcome5          
Outcome6          
Outcome7          
Outcome8          
ALL Combined          
 
Although, as you say, we do not have particularly good power to look at individual outcomes, we 
have looked at stroke and coronary events separately and included these analyses in Supplementary 
Table 18 and in an additional results paragraph in the main text: 
‘Stratification by type of event 
Comparing the separate stroke and coronary event analyses, the PPARGC1 SNP (rs10515638) had a 
larger effect size for coronary events (HR 1.41, P=0.002, 433 events) than for stroke events. By 
contrast, despite much lower power in the stroke analysis, the CNTN4 SNP (rs10510230) had a larger 
effect size for stroke (1.31, P=0.17, 57 events) than for coronary events, especially in those not on 
aspirin (HR 2.71, P=0.003, 26 events), Supplementary Table 18.’ 
 
 
The work described represents original work carried out by the authors and has not been published 
previously, except in the form of an abstract. The article is not under consideration for publication 
elsewhere. Publication of the article is approved by all authors and the responsible authorities 
where the work was carried out. If the article is accepted, it will not be published elsewhere by the 
authors, including electronically in the same form, in English or in any other language, without the 
written consent of the copyright-holder. 
 
 
 
 
________________________________________ 
Nina McCarthy, 25th August 2017, on behalf of all authors. 
 
 
*Statement of Originality
Editor-in-Chief Professor Arnold von Eckardstein 
Institute of Clinical Chemistry 
University Hospital and University of Zurich 
Rämistrasse 100, Zurich 
CH-8091 
Switzerland 
 
25th August 2017 
 
Dear Professor von Eckardstein 
 
Thank you for considering our paper, ‘Genetic Variants in PPARGC1B and CNTN4 are Associated with 
Elevated Thromboxane A2 Formation and with Reduced Cardiovascular Event Free Survival in the 
Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)’ for publication in Atherosclerosis. 
 
This paper describes the first genome wide association study of thromboxane A2 formation, which 
showed that 5 SNPs in two genes, PPARGC1B and CNTN4, are associated with elevated thromboxane 
A2 formation in 806 Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) participants and with an 
excess of cardiovascular events in an independent ASCOT population (n=6,199). Aspirin appears to 
blunt these associations. If specific protection of PPARGC1B and CNTN4 variant carriers by aspirin is 
confirmed, PPARGC1B and CNTN4 genotyping could potentially provide guidance in the use of 
aspirin in primary prevention. 
 
 
Kind regards,  
 
______________________________________ 
 
Nina McCarthy  
Centre for Genetic Origins of Health and Disease (GOHaD) 
University of Western Australia    
Level 5, MRF Building, 50 Murray Street, Perth, WA 6000 
Email:  nina.mccarthy@uwa.edu.au   |    
Tel:  +61 (0)8 92240354 
*Submission Letter   Suggested Reviewers
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Atherosclerosis style guide checklist 
 
Atherosclerosis applies format guidelines to all accepted papers, with the aim of improving their readability. 
 
Manuscripts that do not conform to the format guidelines of the Atherosclerosis Journal will be returned to 
the authors for reformatting. 
 
Please find below a questionnaire to guide authors to comply with the formatting requirements for revised 
submissions. For more detailed information, visit our website.  
 
Please note that when you answer “No” to a question, editing of your manuscript is required before 
submission to Atherosclerosis. 
 
Manuscript structure and style 
Does your manuscript contain all the below essential elements, in this order?     Yes  
(please stick to the headers as indicated below) 
 
- Title  
- Authors, Affiliations, Contact Information 
- Abstract in the Atherosclerosis format (Background and aims, Methods, Results, Conclusions) 
- Introduction 
- Materials and methods (or Patients and methods)  
- Results 
- Discussion 
- Conflict of interest (mandatory) 
- Financial support (if applicable)  
- Author contributions (mandatory)  
- Acknowledgements (if applicable) 
- References 
- Figures and Tables (with legends in the suitable style) 
 
 
Abstract style 
Is the Abstract structured in the below sections?        Yes  
  
- Background and aims 
- Methods 
- Results 
- Conclusions 
 
 
Figure and table legends 
Are figure and table legends formatted as described below?     Yes  
  
Each figure and table legend should have a brief overarching title that describes the entire figure without citing specific 
panels, followed by a description of each panel, and all symbols used.  
 
If a figure or table contains multiple panels, the letter describing each panel should be capitalized and surrounded by 
parenthesis: i.e. (A)(B)(C)(D).  
 
Please make sure to apply the formatting requirements to figures and tables where necessary (e.g. style of p values, 
gene and protein nomenclature). 
 
 
Footnotes to tables            
Are footnotes to tables formatted as described below?      Yes   
 
Footnotes to tables should be listed with superscript lowercase letters, beginning with “
a
.”  
Footnotes must not be listed with numbers or symbols. 
 
 
Abbreviations 
Are abbreviations defined when first used in the text?      Yes  
 
Use of abbreviations should be kept at a minimum. 
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Units 
Are units expressed following the international system of units (SI)?     Yes  
 
If other units are mentioned, please provide conversion factors into SI units. 
 
 
DNA and protein sequences 
Are gene names italicized?          Yes  
 
Gene names should be italicized; protein products of the loci are not italicized.     
  
For murine models, the gene and protein names are lowercase except for the first letter. 
(e.g., gene: Abcb4; protein: Abcb4) 
 
For humans, the whole gene name is capitalized. 
(e.g., gene: ABCB4; protein ABCB4) 
 
 
Mouse strains and cell lines 
Are knock-out or transgenic mouse strains and cell lines italicized and the symbol superscripted? Yes   
 
(e.g. ob/ob , p53
+/+
, p53
-/-
) 
 
 
p values 
Are p values consistently formatted according to the below style throughout the manuscript 
(including figures and tables)?         Yes   
 
p <X 
p >X 
p=X 
 
 
Language 
Is your manuscript written in good English?        Yes   
 
Please make sure that you consistently use either American or British English, but not a mixture of them. 
 
Please make sure that words are written consistently in the same way throughout the manuscript. 
e.g. non-significant or nonsignificant  
e.g. down-regulation or downregulation 
 
 
Artwork 
Have you submitted high-resolution versions of your original artwork?    Yes   
 
Please make sure to use uniform lettering and sizing in your original artwork, including letters to indicate panels, 
consistently throughout all figures.  
